Medeiros Bruno C
Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305-6555, USA.
Best Pract Res Clin Haematol. 2018 Dec;31(4):384-386. doi: 10.1016/j.beha.2018.09.006. Epub 2018 Sep 20.
Despite advances in treatment for acute myeloid leukemia (AML), the prognosis for patients with relapsed disease is extremely poor. The median overall survival for patients with relapsed AML ranges from 4-6 months and long-term survival from the time of relapse ranges from 5%-20%. Much of the difficulty in establishing a standard of care for relapsed AML is that the disease is clinically and genomically diverse. Nevertheless, significant progress has been made over the past 12 months with the approval of several agents, and the expectation is that additional therapies will be available soon. A brief review follows on the progress made in establishing a standard of care for relapsed AML.
尽管急性髓系白血病（AML）的治疗取得了进展，但复发患者的预后极差。复发AML患者的中位总生存期为4至6个月，复发后的长期生存率为5%至20%。为复发AML确立护理标准的一大困难在于，该疾病在临床和基因组方面具有多样性。然而，在过去12个月里，随着几种药物的获批，已取得了显著进展，预计很快会有更多疗法可供使用。以下是关于为复发AML确立护理标准所取得进展的简要综述。
